Radiofrequency ablation cancer therapy, classified under interventional oncology, aims to achieve complete local tumor destruction (coagulative necrosis) without open surgical resection. Under guidance from computed tomography (CT) or ultrasound imaging, interventional radiologists position a needle-like probe into the malignant mass. High-frequency alternating current generates frictional heat exceeding 60 degrees Celsius, killing target cells immediately. The primary clinical goal is achieving complete local tumor control while preserving overall organ function and minimizing recovery time.

1. Patient positioning and pre-procedure safety checks: The patient is placed on the procedure table based on tumor location (supine, prone, or lateral). Monitoring equipment for vital signs, electrocardiogram, and pulse oximetry is attached.
2. Sedation or Anesthesia Administration: Conscious sedation (intravenous analgesics and sedatives) or general endotracheal anesthesia is administered by the anesthesia team to ensure comfort and immobility.
3. Skin Preparation and Sterile Draping: The skin overlying the target organ site is cleansed with antiseptic solution and covered with sterile surgical drapes.
4. Image-Guided Needle Insertion: Using real-time ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), the interventional radiologist inserts a specialized 14- to 17-gauge radiofrequency electrode through a small skin nick into the center of the tumor.
5. Thermal Energy Delivery: Grounding pads attached to the patient's thighs complete the electrical circuit. High-frequency electrical energy is applied, heating the target tissue to 60-100 degrees Celsius for 10 to 30 minutes. Multi-tined electrodes may be expanded to cover larger tumor volumes.
6. Track Ablation and Probe Removal: Once tissue heating is complete, the generator is set to track-ablation mode. Heat is applied as the probe is slowly withdrawn to cauterize the needle path, preventing bleeding and minimizing needle-track tumor seeding.
7. Dressing and Initial Recovery: A sterile adhesive bandage is applied to the puncture site. The patient is transferred to the recovery unit for monitoring.

Clinical evidence highlights several evidence-based advantages of radiofrequency ablation cancer procedures:

• Organ function preservation: Selectively destroys tumor tissue while sparing surrounding healthy liver, kidney, or lung parenchyma.
• Minimally invasive approach: Requires only a small skin puncture, reducing post-operative pain, wound complications, and scar formation.
• Short recovery timeline: Most procedures are outpatient or require brief overnight stays, allowing rapid return to daily activities.
• Repeatability: Can be safely repeated for recurrent localized lesions or combined with systemic therapies like chemotherapy.
• Favorable safety profile: Associated with low major complication rates compared to radical open surgical resection.

Recovery following radiofrequency ablation cancer therapy progresses through initial observation and gradual home rehabilitation:

• First 24 to 48 hours: Bed rest and observation in recovery. Patients may experience mild local pain, nausea, and low-grade fever (post-ablation syndrome). Pain is managed with standard oral analgesics.
• Days 3 to 7: Gradual return to light daily household activities. Fatigue slowly resolves. Heavy lifting and strenuous exercise remain restricted.
• Weeks 2 to 4: Full return to routine work and moderate physical activity. Puncture sites are fully healed.
• Long-term surveillance: Baseline follow-up imaging (contrast CT or MRI) occurs at 1 to 3 months to verify baseline ablation coverage, followed by imaging every 3 to 6 months.

Radiofrequency ablation cancer protocols treat small, localized primary malignancies and secondary metastatic lesions across multiple solid organ sites, including:

• Hepatocellular carcinoma (primary liver cancer) under three to five centimeters
• Colorectal liver metastases with limited lesion numbers
• Renal cell carcinoma (primary kidney cancer) under four centimeters
• Non-small cell lung cancer (primary lung cancer) in non-surgical candidates
• Lung metastases from distinct primary sites
• Osteoid osteoma and painful metastatic bone lesions

1. Pre-Procedure Clinical Evaluation: Comprehensive consultation with an interventional radiologist, including physical examination, medical history review, and baseline functional assessment.
2. Diagnostic Imaging Review: High-resolution contrast-enhanced CT or MRI scans within 30 days prior to the procedure to map tumor size, number, precise anatomical localization, and vascular proximity.
3. Laboratory Blood Testing: Mandatory blood work including complete blood count (CBC), coagulation panel (prothrombin time, INR, activated partial thromboplastin time), liver function tests, and renal function tests (blood urea nitrogen, serum creatinine).
4. Medication Adjustments: Anticoagulants and antiplatelet medications (aspirin, warfarin, clopidogrel, direct oral anticoagulants) must be temporarily discontinued under clinical guidance 3 to 7 days prior to treatment.
5. Pre-Procedure Fasting: Strict fasting from solid foods for 6 to 8 hours and clear liquids for 2 hours prior to scheduled anesthesia.
6. Post-Procedure Transportation Planning: Arranging for a responsible adult companion to drive the patient home following discharge.

Common and Mild Side Effects:
- Post-ablation syndrome: Flu-like symptoms including low-grade fever, fatigue, malaise, and muscle aches occurring in 20% to 35% of patients, lasting 2 to 7 days.
- Mild localized pain or bruising at the needle puncture site.
- Transient shoulder tip pain following liver ablation due to diaphragmatic irritation.

Uncommon Moderate Risks:
- Localized hematoma or minor hemorrhage around the target organ surface (1% to 3%).
- Pleural effusion (fluid around the lungs) following upper liver or lung ablation (2% to 4%).
- Asymptomatic transient elevation of liver enzymes or blood urea nitrogen.

Rare and Serious Complications:
- Thermal damage to adjacent non-target organs: Bowel perforation, bile duct stricture, or gallbladder thermal injury (less than 1%).
- Pneumothorax (collapsed lung) during lung or upper abdominal ablation requiring chest tube insertion (5% to 15% in lung RFA, under 1% in abdominal RFA).
- Severe hemorrhage requiring blood transfusion or transcatheter arterial embolization (less than 1%).
- Abscess formation within the necrotic ablation cavity (1% to 2%).
- Needle track tumor seeding (less than 0.5%).

The clinical journey begins with diagnostic workup, including contrast-enhanced cross-sectional imaging, lab testing for organ function and blood clotting, and anesthetic risk evaluation. On procedure day, the patient receives local anesthesia with conscious sedation or general anesthesia. Using real-time image guidance, the clinician advances the ablation needle into the tumor and applies thermal energy for 10 to 30 minutes. Following treatment, the patient spends two to six hours in post-procedure recovery. Routine discharge occurs the same day or after overnight observation. Serial magnetic resonance imaging (MRI) or CT scans at 1, 3, 6, and 12 months monitor for complete tumor clearance.